Adam Palermo

Adam Palermo is a distinguished scientist and entrepreneur in the field of gene therapy and computational biology. He is currently the Co-Founder and Chief Scientific Officer (CSO) of Source Bio, Inc., a startup he helped establish in January 2023.12

Career Highlights

Academic Background: Adam holds a B.A. in Biochemical Sciences from Harvard University and a Ph.D. in Molecular Pharmacology from Stanford University, where he focused on the genomics of stem cells and nuclear reprogramming.1

Professional Experience: Before co-founding Source Bio, Adam had an impressive career trajectory:

• Decibel Therapeutics: He served as VP of Molecular Platform from June 2020 to December 2022, where he led efforts in computational biology, single-cell genomics, and gene therapy design.1
• Genzyme (Sanofi): Adam held various positions, including Scientific Director of Functional Genomics.1
• Millennium Pharmaceuticals: He worked as a Senior Research Associate from 1998 to 2001.1

Expertise and Contributions

Adam Palermo is recognized for his expertise in:

• Gene therapy
• Computational biology
• Genomics and bioinformatics
• Single-cell genomics
• Process and analytical development in biotechnology

At Decibel Therapeutics, he played a crucial role in driving the company's scientific strategy and leading their initial gene therapy program, DB-OTO, which reached the Investigational New Drug (IND) stage in 2022.1

Current Venture

As the Co-Founder and CSO of Source Bio, Inc., Adam is likely leveraging his extensive experience in gene therapy and computational biology to drive innovation in the biotechnology sector. The company, based in Cambridge, Massachusetts, appears to be focused on ambitious gene therapy projects.13

Adam Palermo's career demonstrates a consistent commitment to advancing genomic sciences and gene therapy, making him a notable figure in the biotechnology industry.